Sort
51,593 grants matching “hepatitis”
Mitigating the Outcomes Associated with the Injection Drug Use Epidemic in Southern Appalachia
$839,468William A Zule · Research Triangle Institute · UH3 · FY2020 · DA
Association of Nutritional and Biochemical Predictors of Body Fat Amount and Distribution with Cancer Risk
$839,461Unhee Lim · University Of Hawaii At Manoa · P01 · FY2015 · CA
Understanding, Predicting and Preventing Type 2 Diabetes in Youth, Boston Clinical Center (UPP Study)
$838,919Elvira Marie Isganaitis · Joslin Diabetes Center · U01 · FY2024 · DK
2/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
$838,879Maria Mori Brooks · University Of Pittsburgh At Pittsburgh · U24 · FY2021 · HL
AlcHepNet DCC UMMS
$838,785Bruce A Barton · Univ Of Massachusetts Med Sch Worcester · U24 · FY2021 · AA
Immune Control and Evasion during Acute HCV Infection
$838,700Georg Michael Lauer · Massachusetts General Hospital · U19 · FY2010 · AI
Saliva Analysis with an Array Sensor
$838,440University Of Texas Austin · U01 · FY2003 · DE
Correlates of protective immunity to HCV and rational vaccine design: Project 3
$838,357Rama Rao Amara · Emory University · U19 · FY2024 · AI
Impact of Structural Racism and Discrimination on Liver Disease Disparities in High-Risk Asian American Populations
$838,349Grace X Ma · Temple Univ Of The Commonwealth · R01 · FY2022 · MD
Therapy of Pulmonary Diseases with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds
$838,276Rudolph Juliano · Initos Pharmaceuticals, Llc · R44 · FY2020 · TR
JCOIN Phase II Economic Research Resource Center
$838,200Sean M. Murphy · Weill Medical Coll Of Cornell Univ · U24 · FY2025 · DA
Towards Evidence-Based Monitoring of Low Dose Methotrexate: CIRT Ancillary Study
$838,133Daniel Hal Solomon · Brigham And Women'S Hospital · R01 · FY2018 · HL
Core B - Developmental
$837,870Ira B Wilson · Miriam Hospital · P30 · FY2022 · AI
Discovery and Assessment of Genetic Determinants of HCV and HIV Control
$837,583Raymond T Chung · Massachusetts General Hospital · R56 · FY2010 · AI
Pharmacogenetics of the Statin Response
$836,840Tufts University Boston · R01 · FY2005 · HL
Infection-homing nanosystems as antibacterial therapeutics-delivery platforms
$836,708Michael J Sailor · University Of California, San Diego · R01 · FY2017 · AI
A Diagnostic Microarray for hemorrhagic fever encephalitis viruses
$836,462David Wang · Washington University · U01 · FY2007 · AI
New Approaches To Active Immunoprophylaxis
$836,285Robert H. Purcell · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
DRW HIV-Ab/HCV-Ab/HBsAg Triplex Rapid Test Submission for FDA-PMA Approval
$836,222Helen H Lee · Diagnostics For The Real World, Ltd · R44 · FY2011 · HL
HEPATITIS C VIRUS PERSISTENCE AND PATHOGENESIS
$836,157University Of Southern California · U19 · FY2004 · AI
Small molecule-induced degradation of dengue proteins as an antiviral strategy
$835,944Priscilla Li-Ning Yang · Stanford University · R01 · FY2023 · AI
Small molecule-induced degradation of dengue proteins as an antiviral strategy
$835,944Priscilla Li-Ning Yang · Stanford University · R01 · FY2024 · AI
Spatial Models of Intrahepatic Hepatitis C Virus Propagation in Humans
$835,913Ruy M Ribeiro · Los Alamos Nat Secty-Los Alamos Nat Lab · R01 · FY2017 · AI
Proteomics Core: Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
$835,849Hanno Steen · Boston Children'S Hospital · U19 · FY2018 · AI
Cardiovascular Disease Mechanisms in HIV Infected and Uninfected Veterans
$835,848Matthew S Freiberg · University Of Pittsburgh At Pittsburgh · R01 · FY2009 · HL